Stivarga Approval History

• FDA approved: Yes (First approved September 27th, 2012)
• Brand name: Stivarga
• Generic name: regorafenib
• Company: Bayer HealthCare Pharmaceuticals
• Treatment for: Colorectal Cancer, Gastrointestinal Stromal Tumor

Stivarga (regorafenib) is an oral multi-kinase inhibitor for the treatment of patients with metastatic colorectal cancer, and gastrointestinal stromal tumors.

FDA Approval History for Stivarga

Date	Article
Feb 25, 2013	FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors
Sep 27, 2012	FDA Approves Stivarga for Advanced Colorectal Cancer
Aug 30, 2012	Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Jun 28, 2012	U.S. FDA Grants Priority Review to the New Drug Application for Bayer's Regorafenib to Treat Patients with Metastatic Colorectal Cancer
May 23, 2012	Bayer Submits New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer

See also...

Stivarga (regorafenib) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.